Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) EBT Margin (2020 - 2025)

Historic EBT Margin for Fennec Pharmaceuticals (FENC) over the last 6 years, with Q3 2025 value amounting to 5.0%.

  • Fennec Pharmaceuticals' EBT Margin rose 768900.0% to 5.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.61%, marking a year-over-year decrease of 147100.0%. This contributed to the annual value of 0.15% for FY2024, which is 753500.0% up from last year.
  • Per Fennec Pharmaceuticals' latest filing, its EBT Margin stood at 5.0% for Q3 2025, which was up 768900.0% from 32.69% recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' EBT Margin ranged from a high of 43522.22% in Q2 2021 and a low of 355.34% during Q1 2023
  • For the 5-year period, Fennec Pharmaceuticals' EBT Margin averaged around 4315.07%, with its median value being 13.3% (2025).
  • As far as peak fluctuations go, Fennec Pharmaceuticals' EBT Margin plummeted by -346502900bps in 2022, and later soared by 4061900bps in 2024.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' EBT Margin stood at 7663.64% in 2021, then tumbled by -85bps to 1130.53% in 2022, then plummeted by -102bps to 26.89% in 2023, then rose by 30bps to 18.94% in 2024, then soared by 74bps to 5.0% in 2025.
  • Its EBT Margin was 5.0% in Q3 2025, compared to 32.69% in Q2 2025 and 13.3% in Q1 2025.